Literature DB >> 2737147

Monoclonal antibodies specific for rat relaxin. IV. Passive immunization with monoclonal antibodies during the antepartum period reduces cervical growth and extensibility, disrupts birth, and reduces pup survival in intact rats.

J J Hwang1, R D Shanks, O D Sherwood.   

Abstract

The purpose of this investigation was to use an approach targeted specifically on endogenous relaxin to determine the influence of antepartum (days 20-22) relaxin on cervical modifications and birth in the rat. To that end, a monoclonal antibody specific for rat relaxin, designated MCA1, was used to neutralize endogenous relaxin in intact pregnant rats. MCA1 or PBS vehicle was administered iv to intact rats daily from days 20-22 of pregnancy. Cervices were removed at 1200 h on day 22. Cervices obtained from MCA1-treated rats were less extensible than cervices obtained from PBS-treated control rats. Furthermore, wet weight, dry weight, water content, and uronate content were lower in cervices obtained from MCA1-treated rats than in cervices from PBS-treated controls. Birth and maternal behavior of MCA1-treated and PBS-treated control rats were observed continuously from 2100 h on day 22 until day 2 postpartum (d2PP). MCA1-treated rats exhibited significantly prolonged durations of litter delivery as well as reduced incidences of live pups on d2PP compared with controls. There were lower incidences of normal maternal behavior observed at birth and on d1PP with MCA1-treated rats than with control rats. In addition, little or no milk was observed in the abdomen of most live pups of MCA1-treated rats on d2PP, whereas abundant milk was observed in the abdomen of all live pups of control rats. The mean live pup weight on d2PP was lower in the litters of MCA1-treated rats than in control litters. The present study indicates that in the rat endogenous relaxin is needed during the antepartum period for normal cervical growth and extensibility, normal litter delivery, and high postpartum pup survival. This work supports the hypothesis that the influence of endogenous relaxin on birth is attributable, at least in part, to its effects on the cervix.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737147     DOI: 10.1210/endo-125-1-260

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Relaxin is essential for renal vasodilation during pregnancy in conscious rats.

Authors:  J Novak; L A Danielson; L J Kerchner; O D Sherwood; R J Ramirez; P A Moalli; K P Conrad
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 2.  New Insights into biological roles of relaxin and relaxin-related peptides.

Authors:  Jae-Il Park; Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

3.  Central administration of porcine relaxin stimulates drinking behaviour in rats: an effect mediated by central angiotensin II.

Authors:  A J Summerlee; G F Robertson
Journal:  Endocrine       Date:  1995-05       Impact factor: 3.633

4.  Relaxin acts on stromal cells to promote epithelial and stromal proliferation and inhibit apoptosis in the mouse cervix and vagina.

Authors:  LiJuan Yao; Alexander I Agoulnik; Paul S Cooke; Daryl D Meling; O David Sherwood
Journal:  Endocrinology       Date:  2008-01-24       Impact factor: 4.736

5.  Relative roles of the epithelial and stromal tissue compartment(s) in mediating the actions of relaxin and estrogen on cell proliferation and apoptosis in the mouse lower reproductive tract.

Authors:  Lijuan Yao; Alexander I Agoulnik; Paul S Cooke; Daryl D Meling; O David Sherwood
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

6.  Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.

Authors:  Gerson Weiss; Sam Teichman; Dennis Stewart; David Nader; Susan Wood; Peter Breining; Elaine Unemori
Journal:  BMC Pregnancy Childbirth       Date:  2016-09-05       Impact factor: 3.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.